Arcadia Biosciences Inc(RKDA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.55 | Insider Own | 15.87% | Shs Outstand | 2.2M | Perf Week | 6.16% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.0M | Perf Month | -36.94% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 18.68% | Short Float | 0.47% | Perf Quarter | -56.39% |
| Income | -0.01B | P/S | 0.15 | EPS this Y | - | Inst Trans | 20.75% | Short Ratio | 0.01 | Perf Half Y | -77.25% |
| Sales | 0.00B | P/B | 1.03 | EPS next 5Y | - | ROA | -162.72% | Short Interest | 0.01M | Perf YTD | -84.95% |
| Book/sh | 0.29 | P/C | 0.17 | EPS past 3/5Y | 59.46% 38.02% | ROE | -430.93% | 52W High | -95.56% ($6.71) | Perf Year | -91.44% |
| Cash/sh | 1.74 | P/FCF | - | Sales past 3/5Y | -13.16% -9.57% | ROIC | -1758.45% | 52W Low | 34.17% ($0.22) | Perf 3Y | -90.23% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 17.56% | Gross Margin | 34.58% | Volatility(W/M) | 14.37% 17.96% | Perf 5Y | -99.65% |
| Dividend TTM | - | EV/Sales | -0.73 | Sales Y/Y TTM | -12.24% | Oper. Margin | -85.52% | ATR (14) | 0.06 | Perf 10Y | -99.98% |
| Dividend Ex-Date | - | Quick Ratio | 2.92 | EPS Q/Q | 35.79% | Profit Margin | -234.53% | RSI (14) | 29.63 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.49 | Sales Q/Q | -0.82% | SMA20 | -21.56% ($0.38) | Beta | 0.57 | Target Price | $12 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -39.22% ($0.49) | Rel Volume | 0.82 | Prev Close | $0.29 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -75.79% ($1.24) | Avg Volume(3M) | 0.93M | Price | $0.3 |
| IPO | 2015/5/15 | Option/Short | No/Yes | Trades | 690 | Volume | 765,538 | Change | 3.94% |
🥥 Plant-based beverage and wellness company. High growth from Zola coconut water. 24% YoY growth in Q2 2025, 30% margins.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded about as much as usual That is 82% of its average volume.
RKDA has a sound balance sheet but weak earning power
Of every $100 in sales, $85.52 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $15. Peers typically go for $44.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +79% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #61 of 61 in the industry
Based on market cap of $1M.
NCRA#57 Nocera Inc $4M PER - 
PAVS#58 Paranovus Entertainment Technology Ltd $3M PER - 
ATPC#59 Agape ATP Corp $2M PER - 
STKH#60 Steakholder Foods Ltd ADR $1M PER - RKDA#61 Arcadia Biosciences Inc $1M PER - 
FAQ
What kind of company is RKDA?
RKDA belongs to the Consumer Defensive sector and operates in the Packaged Foods industry.
What is the market cap of RKDA?
The market cap of RKDA is approximately $1M, ranking 5,893 within its sector.
What is the 52-week high and low for RKDA?
RKDA has recorded a 52-week high of $6.71 and a low of $0.22.
